220470-20-2

Basic information

• Product Name: [3-(4-cyanobenzoylamino)propyl]carbamic acid tert-butyl ester
• Synonyms: [3-(4-cyanobenzoylamino)propyl]carbamic acid tert-butyl ester
• CAS NO: 220470-20-2
• Molecular Weight: 303.361
• Mol File: 220470-20-2.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: [3-(4-cyanobenzoylamino)propyl]carbamic acid tert-butyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: [3-(4-cyanobenzoylamino)propyl]carbamic acid tert-butyl ester(220470-20-2)
• EPA Substance Registry System: [3-(4-cyanobenzoylamino)propyl]carbamic acid tert-butyl ester(220470-20-2)

Safety Data

• Hazardous Substances Data: 220470-20-2(Hazardous Substances Data)

Upstream product

• 75178-96-0 N-Boc-1,3-diaminopropane 
• 6068-72-0 4-cyanobenzoyl chlorIde 
• 57260-71-6 1-t-Butoxycarbonylpiperazine 

Relevant articles and documents

Heterocyclic benzenesulphonamide compounds as bradykinine antagonists

The invention concerns compounds selected among the group consisting of (i) compounds of formula (I) wherein: Het1 represents a nitrogenous heterocycle with 5 apices, in particular imidazole, pyrazole, or triazole; Het2 represents a nitrogenous heterocycle with 4, 5 or 6 apices, selected among the heterocycles: (II) wherein R1and R2are defined as mentioned in the description; and (ii) their additive salts. The invention also concerns the method for preparing said compounds and their use in therapy, in particular for treating pathologies involving bradykinine.

N-benzenesulfonyl-L-proline derivatives, method for preparing and therapeutic use

PCT No. PCT/FR97/02049 Sec. 371 Date May 6, 1999 Sec. 102(e) Date May 6, 1999 PCT Filed Nov. 14, 1997 PCT Pub. No. WO98/24783 PCT Pub. Date Jun. 11, 1998The present invention relates to compounds selected from the group consisting of (i) the compounds of formula I: in which: X is a halogen atom or a methyl group, A is a group -N(R3)CO- or -CO-N(R3)-, B is a single bond, -CH2- or -CH2-O-, R1 is H, a C1-C3 alkyl group or a CF3 group, R2 and R3 are each independently H or a C1-C3 alkyl group, W is CH or N, and n is 2, 3, 4 or 5; and (ii) their addition salts. It further relates to the process for their preparation and to their use in therapeutics, especially for combating pathological conditions involving bradykinin.